I-Mab to develop Genexine's HyLeukin in China

Genexine Inc. (KOSDAQ:095700) granted I-Mab Biopharma (Shanghai, China) exclusive rights to develop and commercialize HyLeukin for cancer in China, Hong Kong, Macau and Taiwan. Genexine will receive an upfront payment and is eligible for development and sales milestones, including $23 million in clinical and regulatory milestones, plus tiered, single-digit royalties. Financial details were not disclosed...